Cancer Immunotherapy Works Better Before 3pm, Study Finds
3 months ago
- #immunotherapy
- #NSCLC
- #circadian-rhythm
- Early time-of-day (ToD) immunochemotherapy significantly improves progression-free survival (PFS) and overall survival (OS) in NSCLC patients.
- Median PFS was 11.3 months in the early ToD group vs. 5.7 months in the late ToD group (HR 0.40, P < 0.001).
- Median OS was 28.0 months in the early ToD group vs. 16.8 months in the late ToD group (HR 0.42, P < 0.001).
- Early ToD treatment enhanced CD8+ T cell activity and increased the ratio of activated to exhausted CD8+ T cells.
- No significant differences in treatment-related adverse events or immune-related adverse events were observed between groups.
- The study supports the importance of circadian timing in immunochemotherapy efficacy for NSCLC.